It has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.